TURKEY CHAPTER

YAVUZ S. SILAY, MD, MBA

ראש פרק

Dr. Silay is currently serving as the Director, Market Access & Health Policy for AIFD( Research Based Pharmaceutical Companies) which the 40 members represent all major global pharmaceutical companies, 650 billion dollars of 1 billion dollar Global Pharmaceutical market. Dr. Silay also serves as CEO of Labiopharma, LLC in US and as the CEO of ICG( Istanbul Consulting Group) in Turkey . He provides guidance to Turkish Ministry of health through a world bank project. His executive team is providing clinical trial administration, market access, medical writing, patient recruitment, retention, regulatory and medical affairs support, drug repositioning for academic institutions and pharmaceutical companies from preclinical to post marketing stages for several years. Dr. Silay is also providing comprehensive and strategic consulting services for the approval of Drugs and Medical Devices and attended several meetings with FDA, EMA, Health Canada and Turkish Health authorities.

Dr. Silay most recently worked as the Vice President, Medical Affairs, and head of Medical Affairs Neurology in the US headquarters Basking Ridge, New Jersey reporting to the President and CEO of Ipsen North America.

Dr.Silay previously worked at Teva Neuroscience from May 2009 through September 2011 as the head of clinical and medical Parkinson’s franchise and the Director of Scientific Affairs and Medical Research in U.S Headquarter in Kansas City reporting to Chief Medical Officer and VP of Medical Affairs. He was previously responsible for the Parkinson’s disease Investigator Initiated Trials, Phase IIIB, Phase IV trials and for developing relationships with Key Opinion Leaders in the field of Neurology.